Analysts at StockNews.com began coverage on shares of Chimerix (NASDAQ:CMRX - Get Free Report) in a report released on Tuesday. The firm set a "hold" rating on the biopharmaceutical company's stock.
Other equities research analysts have also issued reports about the stock. Jefferies Financial Group reiterated a "hold" rating and set a $8.50 price target (down from $10.00) on shares of Chimerix in a research note on Wednesday, March 5th. Wedbush reiterated a "neutral" rating and set a $8.55 target price (up previously from $7.00) on shares of Chimerix in a research report on Wednesday, March 5th. Finally, HC Wainwright reissued a "neutral" rating and issued a $8.55 target price (down from $11.00) on shares of Chimerix in a research report on Wednesday, March 5th.
Read Our Latest Report on Chimerix
Chimerix Price Performance
Shares of CMRX traded down $0.01 during mid-day trading on Tuesday, reaching $8.52. The company's stock had a trading volume of 1,537,676 shares, compared to its average volume of 2,210,031. Chimerix has a 12-month low of $0.75 and a 12-month high of $8.55. The stock has a market cap of $799.21 million, a PE ratio of -9.06 and a beta of -0.17. The company's 50 day moving average is $6.95 and its 200 day moving average is $3.73.
Chimerix (NASDAQ:CMRX - Get Free Report) last announced its quarterly earnings results on Friday, March 21st. The biopharmaceutical company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.01. The company had revenue of $0.06 million during the quarter, compared to analysts' expectations of $0.31 million. As a group, sell-side analysts anticipate that Chimerix will post -0.99 EPS for the current fiscal year.
Insider Buying and Selling
In other Chimerix news, CEO Michael T. Andriole sold 7,370 shares of the stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $4.52, for a total transaction of $33,312.40. Following the completion of the sale, the chief executive officer now directly owns 609,603 shares of the company's stock, valued at approximately $2,755,405.56. This trade represents a 1.19 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold a total of 20,760 shares of company stock worth $91,175 in the last 90 days. Company insiders own 13.10% of the company's stock.
Institutional Investors Weigh In On Chimerix
Several large investors have recently modified their holdings of CMRX. Squarepoint Ops LLC purchased a new position in Chimerix during the 4th quarter worth $130,000. Two Sigma Investments LP increased its stake in shares of Chimerix by 309.1% during the fourth quarter. Two Sigma Investments LP now owns 101,156 shares of the biopharmaceutical company's stock worth $352,000 after acquiring an additional 76,430 shares during the period. OMERS ADMINISTRATION Corp purchased a new position in Chimerix during the fourth quarter worth about $535,000. Millennium Management LLC lifted its position in Chimerix by 6.8% in the fourth quarter. Millennium Management LLC now owns 2,557,530 shares of the biopharmaceutical company's stock valued at $8,900,000 after purchasing an additional 161,795 shares during the period. Finally, Deerfield Management Company L.P. Series C purchased a new stake in Chimerix in the 4th quarter valued at approximately $13,124,000. Hedge funds and other institutional investors own 45.42% of the company's stock.
Chimerix Company Profile
(
Get Free Report)
Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.
See Also
Before you consider Chimerix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chimerix wasn't on the list.
While Chimerix currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
